Table 1 Baseline characteristics of our AML cohort
From: The clinical impact of IKZF1 mutation in acute myeloid leukemia
Characteristics | IKZF1WT group | IKZF1MUT group | P |
|---|---|---|---|
N, % of total | 502, 96.2% | 20, 3.8% | |
Age (years) | 50.0 (11.0–82.0) | 42.5 (15.0–66.0) | 0.032 |
Gender | |||
Male (N) | 220 (43.8%) | 10 (50%) | 0.585 |
Female (N) | 282 (56.2%) | 10 (50%) | |
Peripheral blood | |||
White blood cells (109/L) | 11.30 (0.40–484.80) | 17.72 (1.67–120.00) | 0.533 |
Hemoglobin (g/L) | 83.00 (20.00–204.00) | 92.00 (57.00–148.00) | 0.130 |
Platelets (109/L) | 51.00 (2.00–565.00) | 63.00 (7.00–917.00) | 0.633 |
Bone marrow blasts (%) | 59.5 (11.5–98.0) | 59.0 (20.0–96.0) | 0.559 |
Diagnosis (N) | |||
De novo AML | 481 (95.8%) | 19 (95.0%) | 0.584 |
Secondary/therapy-related AML | 21 (4.2%) | 1 (5.0%) | |
French-American-British (N) | |||
M0 | 21 (4.2%) | 2 (10.0%) | 0.895 |
M1 | 27 (5.4%) | 1 (5.0%) | |
M2 | 170 (33.9%) | 7 (35.0%) | |
M4 | 101 (20.1%) | 5 (25.0%) | |
M5 | 161 (32.1%) | 5 (25.0%) | |
M6 | 11 (2.2%) | 0 (0%) | |
M7 | 1 (0.2%) | 0 (0%) | |
Undefine | 10 (2.0%) | 0 (0%) | |
Cytogenetics (N) | |||
Normal karyotype | 247 (49.2%) | 10 (50.0%) | 0.944 |
Complex karyotype | 44 (8.8%) | 2 (10.0%) | 0.693 |
Monosomal karyotype | 16 (3.2%) | 0 (0%) | 1.000 |
-5/5q-/monosomy 5 | 21 (4.2%) | 0 (0%) | 1.000 |
-7/monosomy 7 | 17 (3.3%) | 0 (0%) | 1.000 |
-17/17p abnormalities | 11 (2.2%) | 0 (0%) | 1.000 |
Chromosome 3 abnormalities | 16 (3.2%) | 2 (10.0%) | 0.148 |
Gene fusions (N) | |||
RUNX1::RUNX1T1 | 65 (12.9%) | 1 (5.0%) | 0.494 |
CBFB::MYH11 | 36 (7.2%) | 0 (0%) | 0.386 |
BCR::ABL1 | 9 (1.8%) | 0 (0%) | 1.000 |
KMT2A rearrangements | 19 (3.8%) | 0 (0%) | 1.000 |
European Leukemia Net 2017 (N) | |||
Low | 151 (30.1%) | 2 (10.0%) | 0.004 |
Intermediate | 212 (42.2%) | 16 (80.0%) | |
High | 139 (27.7%) | 2 (10.0%) | |
Complete remission (N) | 394 (78.5%) | 13 (65.0%) | 0.032 |
No complete remission (N) | 73 (21.5%) | 7 (35.0%) | |